Identification of Human Herpesvirus-8 in Kaposi's Sarcoma with Bullous Pemphigoid.
Wang Tao,Li Cuntao,Yang Chao,Cui Hongzhou,Fu Xuhui,Wen Leilei,Cui Yong,Yang Sen,Zhang Xuejun
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20132100
2014-01-01
Abstract:Kaposi’s sarcoma (KS) is a rare, malignant vascular tumor of the skin, mucosa, and viscera with an increased incidence in human immunodeficiency virus (HIV)-positive patients. According to the clinical characteristics and the affected population, four clinical types of KS have been described successively: classic, endemic to Africa, acquired immunodeficiency syndrome (AIDS)-associated, and immunosuppression associated type. Bullous pemphigoid (BP) is an acquired autoimmune bullous skin disease that frequently occurs in the elderly and is characterized by intraepidermal blisters and immunoglobulin G (IgG) deposits on the basement membrane. A few cases of KS have occurred in immunosuppressed patients with BP. Here, we report a Chinese female patient diagnosed with immunosuppression associated KS that was induced by the short-term use of immunosuppressive agents for BP. We also present a review of the literature on immunosuppressed KS with BP and discuss the potential role of human herpesvirus-8 (HHV-8) in the pathogenic mechanism. METHODS Patient A 68-year-old Chinese woman was referred to First Hospital of Anhui Medical University in July 2009 due to a 7-year history of vesicles and bullae. A physical examination revealed erythematous plaques and large tense bullae on the trunk and all four extremities. A skin biopsy revealed a subepidermal blister containing eosinophils, and the blood vessels were dilated with perivascular infiltrates of a large number of eosinophils (Figure 1C). Histopathology and immunofluorescence studies confirmed the diagnosis of BP. Oral prednisolone (1.0 mg/kg per day) and azathioprine (1.5 mg/kg per day) were administered for BP. The lesions produced scabs, and most of the lesions resolved. Newly emerged asymptomatic violaceous macules and nodules were found on the patient’s feet in October 2009 (Figure 1A). The lesions spread to the torso and extremities (Figure 1B), with a yellow-green discoloration caused by hemorrhage around some of the larger lesions. Histopathology showed a predominance of spindle cells with vascular slits containing numerous intravascular and extravasated erythrocytes and hemosiderin phagocytes. Parts of the nuclei consisted of large, irregular atypia (Figure 1D). Considering the immunosuppressive therapy for BP, a diagnosis of immunosuppressive KS was made.Figure 1.: Clinical and pathological features of immunosuppressive treatment-associated KS in a patient with BP. A: Violaceous macules and nodules on the left foot. B: Violaceous nodules on the left arm. C: A subepidermal blister containing eosinophils (H&E staining, original magnification ×40). D: A predominance of spindle cells with vascular slits containing numerous intravascular and extravasated erythrocytes and hemosiderin phagocytes. Parts of the nuclei consisted of large, irregular atypia (H&E staining, original magnification ×40). E: CT showed multiple high-density nodules in the lung fields before treatment for KS. F: An agarose gel electrophoresis analysis of the nPCR product of HHV-8 DNA from KS lesions from a patient with BP produced a specific, 333-bp fragment (shown in lane 3). HHV-8 DNA was absent from the negative control. Lane 1: DNA marker DL 2000; lane 2: known HHV-8 positive control DNA from classic KS specimens; lane 3: DNA from the patient’s KS specimens; lane 4: distilled water.Laboratory tests, including routine blood tests and liver and kidney function assays, produced values that were all in the range of normal. The serologic test result for HIV was negative. An electrocardiogram indicated ST-T changes and computed tomography (CT) scans showed multiple high-density nodules with clear borders in both sides of the lung fields, suggesting visceral involvement (Figure 1E). The skin lesions and lung nodules responded to treatment with prednisone (0.5 mg/kg per day) and paclitaxel (240 mg/w) for 3 months. Since that time, the patient’s BP has remained in remission, and all the KS lesions including the pulmonary nodules nearly cleared after 6 months. Unfortunately, BP recurred following reduction of medication requiring an increase in dosage. This case is presented to illustrate that immunosuppressive agents may predispose to KS in a brief period, even as short as 3 months. Experimental research Skin biopsy specimens obtained from the KS lesions were stored in liquid nitrogen for reservation. DNA was extracted from skin tissue using a standard phenol-chloroform protocol. The nested polymerase chain reaction (nPCR) assay was used to amplify KS specimens from the patient, with distilled water used as a negative control and known HHV-8 DNA from classic KS specimens used as a positive control. The following primers were used for the nPCR amplification of a 333-bp fragment of the open reading frame 26 (ORF 26) gene from HHV-8: external primers, 5′-ATCTATCCAAGTGCACACTCG-3′ and 5′-CTGGGAACCAAGGCTGATAGG-3′; internal primers, 5′-GATGGATCCCTCTGACAACCT-3′ and 5′-GGATCCGTGTTGTCTACG-3′. A 25 μl reaction system included PCR buffer 2.5 μl, MgCl2 2.4 μl, both of 20 pmol/μl the external primers and the internal primers 1 μl, 5 U/μl tap enzyme 0.5 μl, 2.5 mmol/L dNTP 2.5 μl, DNA template (4 μl in the first stage and 2 μl in the second stage) and distilled water. The samples were amplified for 35 cycles and the products were analyzed on 1.5% agarose gels containing ethidium bromide at 100 V of constant voltage for 50 minutes. RESULTS Agarosegel electrophoresis analysis showed that HHV-8 DNA was present in both the patient’s KS specimens and the classic KS specimens (positive control) and was absent from the negative control (Figure 1F). Review of the literature There are 12 reports of KS associated with BP in the PubMed database. Here, we review these 12 cases (including the case described above), including the age of onset, sex, type and dose of medication for BP, as well as other aspects, which are summarized in Table 1.Table 1: Clinical characteristics of BP patients treated with immunosuppressive agents who later developed KSThe 12 patients consisted of five males and seven females who had a mean age of 76.7 years (range, 62 to 87 years). All the patients had BP before KS developed, and all were taking glucocorticosteroids. Prednisone was administered at doses ranging from 25 to 80 mg/d for periods ranging from 22 days to 9 years. Seven patients were administered azathioprine in addition to prednisone. All the patients were directed to reduce the dosage of the immunosuppressive drugs after the onset of KS. After some time, BP and KS had not recurred in 5 cases (Cases 1, 2, 4, 5, and 8), and the immunosuppressive drugs were cautiously discontinued in 3 of these patients (cases 1, 4, and 5) with no recurrence of blisters. Interferon, combined with a reduction in the prednisone dose, was prescribed for KS in cases 2 and 6. In cases 4 and 6, radiotherapy led to a reduction in the size and number of the lesions. Case 3 died one year later out of hospital because the BP recurred and KS spread rapidly throughout almost the entire body. Case 10 died following a cardiac infarction, and case 11 died from sudden, massive gastrointestinal bleeding with insufficient evidence that it was related to KS. This review of the literature led to our development of 3 key concepts. First, the use of immunosuppressive drugs affects the development of KS and may increase susceptibility to HHV-8 infection. Second, aging may be another trigger for KS in patients with BP. Finally, there was no definite link between the corticoid dosage and the time interval from the initiation of immunosuppressive therapy to the first sign of KS. DISCUSSION Immunosuppression associated KS was first identified and has been widely reported in immunosuppressed organ transplant recipients.1 Less commonly, KS has been reported in patients receiving immunosuppressive drugs to control BP. This case constituted the third report of KS associated with BP and the first report of the presence of HHV-8 in immunosuppressive KS with BP in Han Chinese patients. Treatment of immunosuppressive treatment-associated KS is directed toward reducing the immunosuppressive agents. If KS lesions still extended, chemotherapy can be implemented. Successful treatment has also been reported with paclitaxel which has a powerful anti-tumor effect. Radiotherapy can be a good local therapeutic choice especially in non-AIDS associated KS resulting great response rate. Besides, therapeutic options for KS also include nonintervention, surgery, laser surgery and anti-HHV8 therapy based on clinical type, disease stage, progression pattern and distribution.2 As the treatment goals are not only to reduce the skin lesions but also to alleviate gut involvement, the combination of local and systemic treatment options may be preferable. HHV-8, also known as KS-associated herpesvirus (KSHV), was first identified in a study of AIDS-related KS and had been detected in all four types of KS as of 1994.2 HHV-8 has been identified as a risk factor for the development of all types of KS.3 Because HHV-8 encodes many homologs of human genes, this virus can stimulate biological processes such as inflammation, cell proliferation, and angiogenesis, and it can likely inhibit apoptosis.4 The host immune response and the cytokines released by HHV-8 and the related herpesvirus-infected cells may lead to cell proliferation and tumorigenesis in susceptible patients.5 Over 95% of KS lesions have been found to be infected with HHV-8, and HHV-8 DNA has been detected in peripheral blood mononuclear cells from healthy individuals. Therefore, HHV-8 is considered a necessary, but not sufficient, etiologic factor for the development of KS. We detected HHV-8 DNA in KS samples in this study. In addition, we listed other 3 cases with HHV-8 detection in Table 1. This result further supports the hypothesis that HHV-8 is a latent human herpesvirus activated by immunosuppressive therapy in genetically susceptible patients and may be related to the pathogenesis of KS. However, we also need to examine the complex relationships among immunological, genetic, and environmental factors, as well as aging. Acknowledgments: We are most grateful to all the members who have participated in this study.